AAV Gene Delivery of BCKD Subunits for MSUD Enzyme Restoration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Maple Syrup Urine Disease (MSUD), such as dietary BCAA restriction and liver transplantation, are inadequate in preventing life-threatening crises and pose significant risks.
Innovation Solution
Administering a recombinant Adeno-associated virus (rAAV) vector containing engineered nucleic acid to express functional BCKDHA and/or BCKDHB proteins in the liver and/or skeletal muscle to compensate for loss-of-function mutations, using codon-optimized genes and AAV9 capsids for targeted gene therapy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If liver transplantation is performed to treat MSUD, then BCKD enzyme activity is restored, but surgical risks and long-term immunosuppression occur
Solution Approach 1:
The patent uses AAV vectors as intermediaries to deliver functional BCKDHA and BCKDHB genes to patient cells. The viral vector acts as a mediator between the therapeutic gene and the target cells, enabling gene transfer without surgical intervention and avoiding the need for organ transplantation and its associated risks
Solution Approach 2:
The patent replaces the mechanical surgical procedure of liver transplantation with a non-invasive or minimally invasive gene delivery system. Instead of physically transplanting an organ, the therapy uses viral vectors to deliver genetic material that restores enzyme function in situ
2Quantity of substance
If dietary BCAA restriction is implemented to treat MSUD, then BCAA levels are controlled, but treatment efficacy is imperfect and encephalopathic crises cannot be prevented
Solution Approach 1:
The patent applies preliminary action by restoring the defective BCKD enzyme function through gene therapy before metabolic crises can occur. By correcting the genetic defect, the enzyme system is prepared to properly metabolize BCAAs under normal physiological conditions, eliminating the need for restrictive dietary measures
Solution Approach 2:
The patent enables the patient's own metabolic system to serve its normal function by restoring BCKD enzyme activity through gene therapy. The corrected enzyme system automatically regulates BCAA metabolism without requiring external dietary control or monitoring
3Object-affected harmful factors
If rAAV gene therapy is administered to express BCKDHA/BCKDHB, then BCKD enzyme activity is restored without surgical risks, but the complexity of viral vector engineering increases
Solution Approach 1:
The patent segments the therapeutic approach into modular components: AAV vector construction, transgene design (BCKDHA and BCKDHB cDNAs), promoter selection, and delivery methodology. This segmentation allows each component to be independently optimized and tested, managing the overall complexity of the gene therapy system
Data Source
AI summary
In some aspects the disclosure provides compositions and methods for promoting expression of functional BCKDHA protein, which is the E1-alpha subunit of the branched-chain alpha-keto acid (BCAA) dehydrogenase complex, in a subject. In some aspects the disclosure provides compositions and methods for promoting expression of functional BCKDHB protein, which is the E1-beta subunit of the branched-chain alpha-keto acid (BCAA) dehydrogenase complex, in a subject. In some aspects the disclosure provides compositions and methods for promoting expression of functional BCKDHA and BCKDHB proteins, in a subject. In some embodiments, the disclosure provides methods of treating a subject having Maple Syrup Urine Disease (MSUD).